Abstract Details

Title Cortical and Subcortical Grey Matter Atrophy as Predictors of Disability Progression in Patients with Multiple Sclerosis: A 10-Year Follow-Up Study

Topic MS and Related Diseases

Presentation(s) P06 - (-)

Poster/Presentation
Number 118

Objective

Background BACKGROUND: The search for reliable MRI markers to predict disease progression in MS is ongoing for more than two decades. The evolution of gray matter (GM) atrophy appears to commence early in the disease, but the true rate of GM atrophy evolution over long-term is unknown at this time. Further research on the better understanding of evolution of GM atrophy over long-term and its relation to disability progression is warranted and requires a long-term longitudinal study design.

Design/Methods DESIGN/METHODS: Brain magnetic resonance imaging (MRI) using 1.5 T scanners and clinical neurological assessment was performed on 81 patients at time at baseline and follow-up visits after 5 and 10 years. T1- and T2-lesion volumes (LVs) were calculated. Global and tissue specific atrophy changes were longitudinally assessed by using direct measurement approach. Tissue volumes for the SDGM structures were also obtained. Disability progression was defined as an increase in Expanded Disability Status Scale of ?1.0 at 5 and 10 year follow-up.

Results RESULTS: Over 5 years, patients with disability progression showed significantly increased loss of whole brain (-3.75% vs. -1.98%, p<.001), cortical (-3.44% vs. -1.83%, p=.009) and putamen volume changes (-10.56% vs. -3.81%, p=.003) compared to patients without disability progression. Over 10 years, there was a trend for greater decrease in whole brain volume (-5.54% vs. -3.73%, p=.015) in the disability progressed group.

Conclusions CONCLUSIONS: This long-term study shows that cortical and SDGM atrophy occurs early in the course of MS and is associated with disability progression at 5, but not 10 years of follow-up. Over 10 years, whole brain atrophy showed better predictive value for disability progression than tissue specific GM measures.

Authors/Disclosures
Cecilie O. Jacobsen, MD (Stavanger University Hospital) PRESENTER	No disclosure on file
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)	Prof. Bergsland has nothing to disclose.
Turi Dalaker	No disclosure on file
Elisabeth Farbu (Stavanger Univ.Sjukehus)	No disclosure on file
Jesper Hagemeier	No disclosure on file
Jan P. Larsen (Rogaland Central Hospital)	No disclosure on file
	No disclosure on file
Kjell Morten Myhr, MD (Haukeland University Hospital)	No disclosure on file
Harald Nyland (Haukeland Unversity Hospital)	No disclosure on file
	No disclosure on file
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center)	The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Michael A. Panzara, MD, MPH	Dr. Panzara has received personal compensation for serving as an employee of Neurvati Neurosciences. Dr. Panzara has received personal compensation for serving as an employee of GRIN Therapeutics. Dr. Panzara has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Wave Life Sciences. Dr. Panzara has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Athira Pharma. Dr. Panzara has stock in GRIN Therapeutics. Dr. Panzara has stock in Cadenza Bio. Dr. Panzara has stock in Athira Pharma. Dr. Panzara has stock in Wave Life Sciences. Dr. Panzara has stock in Sanofi.

��ɫ��

��ɫ��